BrainStorm Chief Medical Advisor Featured on Israel Radio Broadcast

BrainStorm Cell Therapeutics Inc., a developer of adult stem cell technologies and therapeutics, announced that its chief medical advisor, Professor Eldad Melamed, was interviewed on November 9, on Israel's radio broadcast, Galei Zahal.

The interview was conducted by Yaron Willensky, a news talk show host, to discuss the latest achievements, treatment and progress of BrainStorm's stem cell technology and therapy with respect to neurodegenerative diseases such as ALS and Parkinson's disease.

"The stem cell therapy treatment is ready. We have successfully been able to process autologous adult human mesenchymal stem cells, grow them and differentiate them into other cell types for the treatment of neurodegenerative diseases. We are currently in middle of obtaining approval to begin the first clinical trials on ALS patients in Israel," said Melamed during the interview. "Regarding clinical trials for Parkinson's disease, we are ready to begin," said Melamed. "However, we must still complete the regulatory approval process before that can happen."

"The interview with Professor Eldad Melamed, BrainStorm's chief medical advisor, on Israeli national radio demonstrates the continuing acceptance of the need for stem cell therapies and recognizes the scientific achievements of BrainStorm and its team," said Rami Efrati, CEO of BrainStorm.

BrainStorm Cell Therapeutics Inc. is a company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases.

More Information:

http://www.brainstorm-cell.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))

Related terms: advisor, ceo, clinical, disease, israel, products, radio, technology